Pembrolizumab, Ibrutinib and Rituximab in PCNSL

• Status: Recruiting
• Trial end date: 2024-03-05

Summary

This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL).

The three drugs being used in the study are:

• Pembrolizumab (MK3475)

• Ibrutinib

• Rituximab

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Pembrolizumab; Rituximab